GLP-1 Plateau Management forProviders

1. Medication Optimization

Clinical Definition: Dose escalation should only proceed if the patient has tolerated the current dose ≥4 weeks and has room within the labeled titration schedule.

Key questions:
Is the patient at maximum tolerated dose, or is there room to titrate up?Would switching within-class (e.g., semaglutide → tirzepatide) offer additional benefit?
Is a drug holiday or dose reduction indicated for side-effect management first?

2. Nutrition Intervention

• Protein & Macros
• Increase protein to 1.2-1.6g/kg body weight
• Reduce ultra-processed/high-calorie-density foods
• Address "calorie creep" identified in food diary
• Structured Support
• Refer to registered dietitian if not already involved
• Consider structured meal replacement short-term
• Reassess hydration and fiber intake

3.  Activity Intervention

• Resistance Training — Introduce or increase 2-3x/week to preserve lean mass and raise metabolic rate
• NEAT Optimization — Target 7,000-10,000 steps/day; address sedentary work patterns
• Structured Cardio — 150+ min/week moderate intensity if not contraindicated

4.  Behavioral & Psychological Support

• Refer to behavioral health for emotional eating, stress-related eating
• Reinforce non-scale victories (energy, labs, clothing fit) to prevent disengagement
• Screen for depression/anxiety exacerbating plateau

5. Medical Optimization

Recommendation Box: Address any underlying conditions identified in Medical Workup (hypothyroidism, sleep apnea, medication interactions) before escalating GLP-1 dose further.

• Treat identified thyroid, sleep, or hormonal contributors
• Discontinue or switch weight-promoting concurrent medications where clinically feasible
• Consider adjunct therapy only after lifestyle and medication optimization attempted

1. Confirm True Plateau

Less than 2% weight loss over 3 consecutive months + confirmed adherence → proceed. If adherence is uncertain → address adherence first, re-assess in 4 weeks.

Key questions:
Is the patient at maximum tolerated dose, or is there room to titrate up?Would switching within-class (e.g., semaglutide → tirzepatide) offer additional benefit?
Is a drug holiday or dose reduction indicated for side-effect management first?

2. Rule Out Medical Causes

• Labs abnormal? → Treat underlying condition (thyroid, Cushing's, medication interaction) before continuing algorithm
• Labs normal? → Proceed to Step 3

3.  Assess Dose Status

• Not at max tolerated dose → Escalate per titration schedule → Reassess in 4-6 weeks
• At max dose, tolerating well → Proceed to Step 4
• At max dose, poor tolerance → Consider dose reduction or switch within class

4.  Lifestyle Factor Check

• Dietary intake adequate & accurate? → If no → Nutrition intervention (see Interventions tab)
• Physical activity adequate? → If no → Activity intervention
• Sleep/stress optimized? → If no → Refer accordingly

5. Reassess After Intervention (4-8 weeks)

• Weight loss resumes → Continue current plan, routine follow-up
• No change → Consider combination therapy, specialist referral, or re-evaluate goals with patient
• Weight regain → Full reassessment of adherence, medical, and psychological factors

1. Plateau Visit Note Template

Structure: Subjective (patient-reported symptoms/adherence) → Objective (weight, labs, body composition) → Assessment (true plateau vs. expected slowing) → Plan (intervention selected, follow-up interval)

Key questions to document:

• Duration of current dose and adherence pattern
• Rate of weight loss pre-plateau vs. current
• Which interventions were discussed and selected
• Follow-up interval and reassessment criteria

2. Patient Counseling Documentation

• Education provided — Note specific plateau explanation given to patient
• Shared decision-making — Document patient's stated priorities and agreed-upon plan
• Informed consent — Note discussion of dose changes, risks/benefits if applicable

3. Coding & Billing Considerations

• E/M level — Typically supports moderate complexity given chronic disease management with treatment adjustment
• ICD-10 considerations — Document underlying obesity/overweight code plus any newly identified comorbidity (e.g., hypothyroidism)
• Time-based billing — If counseling exceeds 50% of visit, consider time-based E/M coding

4.  Follow-Up Scheduling

Recommendation Box: Standard follow-up interval after a plateau intervention is 4-8 weeks, shorter if dose was adjusted or new medical issue identified.

• Document next visit date and specific reassessment metrics (weight, waist circumference, labs if applicable)
• Flag chart for early follow-up if red-flag symptoms discussed